Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas
To describe the patterns of recurrence and the prognosis of patients with a recurrent TP53 mutated endometrial carcinoma treated initially by surgery. All patients with endometrial carcinoma, treated at hospital European Georges Pompidou between 2001 and 2021 were retrospectively included. Patients...
Gespeichert in:
| Veröffentlicht in: | European journal of surgical oncology 2023-09, Vol.49 (9), p.106954-106954, Article 106954 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106954 |
|---|---|
| container_issue | 9 |
| container_start_page | 106954 |
| container_title | European journal of surgical oncology |
| container_volume | 49 |
| creator | Pain, Flore-Anne Beinse, Guillaume Azaïs, Henri Auvray-Kuentz, Marie Garcin, Louis-Marie Delanoy, Nicolas Bentivegna, Enrica Benoit, Louise Nguyen-Xuan, Huyen-Thu Blons, Hélène Fabiano, Emmanuelle LE Frère Belda, Marie-Aude Bats, Anne-Sophie Koual, Meriem |
| description | To describe the patterns of recurrence and the prognosis of patients with a recurrent TP53 mutated endometrial carcinoma treated initially by surgery.
All patients with endometrial carcinoma, treated at hospital European Georges Pompidou between 2001 and 2021 were retrospectively included. Patients were separated into two groups: TP53-mutated and not TP53-mutated (POLE/ultramutated-like (POLEmut), dMMR (mismatch repair-deficient) and NSMP (No specific molecular profile)). We estimated survival using recurrence free survival, overall survival and overall survival from recurrence. The risk of recurrence according to TP53 status and the type of recurrence (locoregional recurrence, peritoneal recurrence, and metastasis) were also compared between the two groups.
Two hundred and ninety-one patients with endometrial carcinoma were included. Of these, 57 were TP53-mutated and 234 patients were not TP53-mutated. TP53 mutated patients had the worst recurrence free survival and overall survival (p |
| doi_str_mv | 10.1016/j.ejso.2023.06.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2829430071</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0748798323005437</els_id><sourcerecordid>2829430071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-1b3afe5a4c306e936239d34ad290812e31a50d254f093034a16ff872eb9f96c93</originalsourceid><addsrcrecordid>eNp9kD1rHDEQhkWIic-X_IEUQWWa3Yyk_RK4MYe_4MAuLk0aodOOjI7dlS1pE_zvrfXZKV0NM-87LzMPId8ZlAxY8-tQ4iH6kgMXJTQlQPOJrFgteMFZ3X4mK2irrmhlJ07JWYwHAJCilV_IqWhFJVktV-TPvU4JwxSptzSgmUPAySB1E41zeHBGD8MzTQF1wp7-8yNO1PpAd_e1KMY5vY5x6rOQgtMDNToYN_lRx6_kxOoh4re3uia_ry53m5tie3d9u7nYFkZAmwq2F9piravcNihFw4XsRaV7LqFjHAXTNfS8rmy-HrLAGmu7luNeWtkYKdbk5zH3MfinGWNSo4sGh0FP6OeoeMdlJQBalq38aDXBxxjQqsfgRh2eFQO1MFUHtTBVC1MFjcpM89KPt_x5P2L_f-UdYjacHw2Yv_zrMKho3EKxd5loUr13H-W_AKQTiDU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829430071</pqid></control><display><type>article</type><title>Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas</title><source>Elsevier ScienceDirect Journals</source><creator>Pain, Flore-Anne ; Beinse, Guillaume ; Azaïs, Henri ; Auvray-Kuentz, Marie ; Garcin, Louis-Marie ; Delanoy, Nicolas ; Bentivegna, Enrica ; Benoit, Louise ; Nguyen-Xuan, Huyen-Thu ; Blons, Hélène ; Fabiano, Emmanuelle ; LE Frère Belda, Marie-Aude ; Bats, Anne-Sophie ; Koual, Meriem</creator><creatorcontrib>Pain, Flore-Anne ; Beinse, Guillaume ; Azaïs, Henri ; Auvray-Kuentz, Marie ; Garcin, Louis-Marie ; Delanoy, Nicolas ; Bentivegna, Enrica ; Benoit, Louise ; Nguyen-Xuan, Huyen-Thu ; Blons, Hélène ; Fabiano, Emmanuelle ; LE Frère Belda, Marie-Aude ; Bats, Anne-Sophie ; Koual, Meriem</creatorcontrib><description>To describe the patterns of recurrence and the prognosis of patients with a recurrent TP53 mutated endometrial carcinoma treated initially by surgery.
All patients with endometrial carcinoma, treated at hospital European Georges Pompidou between 2001 and 2021 were retrospectively included. Patients were separated into two groups: TP53-mutated and not TP53-mutated (POLE/ultramutated-like (POLEmut), dMMR (mismatch repair-deficient) and NSMP (No specific molecular profile)). We estimated survival using recurrence free survival, overall survival and overall survival from recurrence. The risk of recurrence according to TP53 status and the type of recurrence (locoregional recurrence, peritoneal recurrence, and metastasis) were also compared between the two groups.
Two hundred and ninety-one patients with endometrial carcinoma were included. Of these, 57 were TP53-mutated and 234 patients were not TP53-mutated. TP53 mutated patients had the worst recurrence free survival and overall survival (p < 0.001 for each). The hazard rate of recurrence was higher during the first three years for TP53 mutated endometrial carcinoma then tend to join the one of no TP53 mutated. There was a statistical difference between the two groups in terms of cumulative incidence of peritoneal recurrence (p = 0.002). There was, however, no statistical difference in overall survival from recurrence.
TP53-mutated endometrial carcinoma were more likely to experience a recurrence during the first three years and most often peritoneal recurrence compared to not TP53-mutated. TP53 status in endometrial carcinoma could be useful to define follow-up. Further prospective studies are required to assess the predictive impact of TP53 mutation on chemotherapy benefit.
•TP53-mutated endometrial carcinoma had the worst recurrence free survival and overall survival.•TP53-mutated endometrial carcinoma were more likely to experience a recurrence during the first three years.•TP53 mutated endometrial cancer recurrences were often distant recurrence (peritoneal) compared to not TP53-mutated.</description><identifier>ISSN: 0748-7983</identifier><identifier>EISSN: 1532-2157</identifier><identifier>DOI: 10.1016/j.ejso.2023.06.006</identifier><identifier>PMID: 37349159</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Endometrial cancer ; Local recurrence ; Recurrence ; Survival ; TP53-Mutation</subject><ispartof>European journal of surgical oncology, 2023-09, Vol.49 (9), p.106954-106954, Article 106954</ispartof><rights>2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology</rights><rights>Copyright © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-1b3afe5a4c306e936239d34ad290812e31a50d254f093034a16ff872eb9f96c93</cites><orcidid>0000-0001-8558-4524 ; 0000-0002-1280-1847 ; 0000-0003-2731-6462</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejso.2023.06.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37349159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pain, Flore-Anne</creatorcontrib><creatorcontrib>Beinse, Guillaume</creatorcontrib><creatorcontrib>Azaïs, Henri</creatorcontrib><creatorcontrib>Auvray-Kuentz, Marie</creatorcontrib><creatorcontrib>Garcin, Louis-Marie</creatorcontrib><creatorcontrib>Delanoy, Nicolas</creatorcontrib><creatorcontrib>Bentivegna, Enrica</creatorcontrib><creatorcontrib>Benoit, Louise</creatorcontrib><creatorcontrib>Nguyen-Xuan, Huyen-Thu</creatorcontrib><creatorcontrib>Blons, Hélène</creatorcontrib><creatorcontrib>Fabiano, Emmanuelle</creatorcontrib><creatorcontrib>LE Frère Belda, Marie-Aude</creatorcontrib><creatorcontrib>Bats, Anne-Sophie</creatorcontrib><creatorcontrib>Koual, Meriem</creatorcontrib><title>Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas</title><title>European journal of surgical oncology</title><addtitle>Eur J Surg Oncol</addtitle><description>To describe the patterns of recurrence and the prognosis of patients with a recurrent TP53 mutated endometrial carcinoma treated initially by surgery.
All patients with endometrial carcinoma, treated at hospital European Georges Pompidou between 2001 and 2021 were retrospectively included. Patients were separated into two groups: TP53-mutated and not TP53-mutated (POLE/ultramutated-like (POLEmut), dMMR (mismatch repair-deficient) and NSMP (No specific molecular profile)). We estimated survival using recurrence free survival, overall survival and overall survival from recurrence. The risk of recurrence according to TP53 status and the type of recurrence (locoregional recurrence, peritoneal recurrence, and metastasis) were also compared between the two groups.
Two hundred and ninety-one patients with endometrial carcinoma were included. Of these, 57 were TP53-mutated and 234 patients were not TP53-mutated. TP53 mutated patients had the worst recurrence free survival and overall survival (p < 0.001 for each). The hazard rate of recurrence was higher during the first three years for TP53 mutated endometrial carcinoma then tend to join the one of no TP53 mutated. There was a statistical difference between the two groups in terms of cumulative incidence of peritoneal recurrence (p = 0.002). There was, however, no statistical difference in overall survival from recurrence.
TP53-mutated endometrial carcinoma were more likely to experience a recurrence during the first three years and most often peritoneal recurrence compared to not TP53-mutated. TP53 status in endometrial carcinoma could be useful to define follow-up. Further prospective studies are required to assess the predictive impact of TP53 mutation on chemotherapy benefit.
•TP53-mutated endometrial carcinoma had the worst recurrence free survival and overall survival.•TP53-mutated endometrial carcinoma were more likely to experience a recurrence during the first three years.•TP53 mutated endometrial cancer recurrences were often distant recurrence (peritoneal) compared to not TP53-mutated.</description><subject>Endometrial cancer</subject><subject>Local recurrence</subject><subject>Recurrence</subject><subject>Survival</subject><subject>TP53-Mutation</subject><issn>0748-7983</issn><issn>1532-2157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kD1rHDEQhkWIic-X_IEUQWWa3Yyk_RK4MYe_4MAuLk0aodOOjI7dlS1pE_zvrfXZKV0NM-87LzMPId8ZlAxY8-tQ4iH6kgMXJTQlQPOJrFgteMFZ3X4mK2irrmhlJ07JWYwHAJCilV_IqWhFJVktV-TPvU4JwxSptzSgmUPAySB1E41zeHBGD8MzTQF1wp7-8yNO1PpAd_e1KMY5vY5x6rOQgtMDNToYN_lRx6_kxOoh4re3uia_ry53m5tie3d9u7nYFkZAmwq2F9piravcNihFw4XsRaV7LqFjHAXTNfS8rmy-HrLAGmu7luNeWtkYKdbk5zH3MfinGWNSo4sGh0FP6OeoeMdlJQBalq38aDXBxxjQqsfgRh2eFQO1MFUHtTBVC1MFjcpM89KPt_x5P2L_f-UdYjacHw2Yv_zrMKho3EKxd5loUr13H-W_AKQTiDU</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Pain, Flore-Anne</creator><creator>Beinse, Guillaume</creator><creator>Azaïs, Henri</creator><creator>Auvray-Kuentz, Marie</creator><creator>Garcin, Louis-Marie</creator><creator>Delanoy, Nicolas</creator><creator>Bentivegna, Enrica</creator><creator>Benoit, Louise</creator><creator>Nguyen-Xuan, Huyen-Thu</creator><creator>Blons, Hélène</creator><creator>Fabiano, Emmanuelle</creator><creator>LE Frère Belda, Marie-Aude</creator><creator>Bats, Anne-Sophie</creator><creator>Koual, Meriem</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8558-4524</orcidid><orcidid>https://orcid.org/0000-0002-1280-1847</orcidid><orcidid>https://orcid.org/0000-0003-2731-6462</orcidid></search><sort><creationdate>20230901</creationdate><title>Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas</title><author>Pain, Flore-Anne ; Beinse, Guillaume ; Azaïs, Henri ; Auvray-Kuentz, Marie ; Garcin, Louis-Marie ; Delanoy, Nicolas ; Bentivegna, Enrica ; Benoit, Louise ; Nguyen-Xuan, Huyen-Thu ; Blons, Hélène ; Fabiano, Emmanuelle ; LE Frère Belda, Marie-Aude ; Bats, Anne-Sophie ; Koual, Meriem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-1b3afe5a4c306e936239d34ad290812e31a50d254f093034a16ff872eb9f96c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Endometrial cancer</topic><topic>Local recurrence</topic><topic>Recurrence</topic><topic>Survival</topic><topic>TP53-Mutation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pain, Flore-Anne</creatorcontrib><creatorcontrib>Beinse, Guillaume</creatorcontrib><creatorcontrib>Azaïs, Henri</creatorcontrib><creatorcontrib>Auvray-Kuentz, Marie</creatorcontrib><creatorcontrib>Garcin, Louis-Marie</creatorcontrib><creatorcontrib>Delanoy, Nicolas</creatorcontrib><creatorcontrib>Bentivegna, Enrica</creatorcontrib><creatorcontrib>Benoit, Louise</creatorcontrib><creatorcontrib>Nguyen-Xuan, Huyen-Thu</creatorcontrib><creatorcontrib>Blons, Hélène</creatorcontrib><creatorcontrib>Fabiano, Emmanuelle</creatorcontrib><creatorcontrib>LE Frère Belda, Marie-Aude</creatorcontrib><creatorcontrib>Bats, Anne-Sophie</creatorcontrib><creatorcontrib>Koual, Meriem</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pain, Flore-Anne</au><au>Beinse, Guillaume</au><au>Azaïs, Henri</au><au>Auvray-Kuentz, Marie</au><au>Garcin, Louis-Marie</au><au>Delanoy, Nicolas</au><au>Bentivegna, Enrica</au><au>Benoit, Louise</au><au>Nguyen-Xuan, Huyen-Thu</au><au>Blons, Hélène</au><au>Fabiano, Emmanuelle</au><au>LE Frère Belda, Marie-Aude</au><au>Bats, Anne-Sophie</au><au>Koual, Meriem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas</atitle><jtitle>European journal of surgical oncology</jtitle><addtitle>Eur J Surg Oncol</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>49</volume><issue>9</issue><spage>106954</spage><epage>106954</epage><pages>106954-106954</pages><artnum>106954</artnum><issn>0748-7983</issn><eissn>1532-2157</eissn><abstract>To describe the patterns of recurrence and the prognosis of patients with a recurrent TP53 mutated endometrial carcinoma treated initially by surgery.
All patients with endometrial carcinoma, treated at hospital European Georges Pompidou between 2001 and 2021 were retrospectively included. Patients were separated into two groups: TP53-mutated and not TP53-mutated (POLE/ultramutated-like (POLEmut), dMMR (mismatch repair-deficient) and NSMP (No specific molecular profile)). We estimated survival using recurrence free survival, overall survival and overall survival from recurrence. The risk of recurrence according to TP53 status and the type of recurrence (locoregional recurrence, peritoneal recurrence, and metastasis) were also compared between the two groups.
Two hundred and ninety-one patients with endometrial carcinoma were included. Of these, 57 were TP53-mutated and 234 patients were not TP53-mutated. TP53 mutated patients had the worst recurrence free survival and overall survival (p < 0.001 for each). The hazard rate of recurrence was higher during the first three years for TP53 mutated endometrial carcinoma then tend to join the one of no TP53 mutated. There was a statistical difference between the two groups in terms of cumulative incidence of peritoneal recurrence (p = 0.002). There was, however, no statistical difference in overall survival from recurrence.
TP53-mutated endometrial carcinoma were more likely to experience a recurrence during the first three years and most often peritoneal recurrence compared to not TP53-mutated. TP53 status in endometrial carcinoma could be useful to define follow-up. Further prospective studies are required to assess the predictive impact of TP53 mutation on chemotherapy benefit.
•TP53-mutated endometrial carcinoma had the worst recurrence free survival and overall survival.•TP53-mutated endometrial carcinoma were more likely to experience a recurrence during the first three years.•TP53 mutated endometrial cancer recurrences were often distant recurrence (peritoneal) compared to not TP53-mutated.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37349159</pmid><doi>10.1016/j.ejso.2023.06.006</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-8558-4524</orcidid><orcidid>https://orcid.org/0000-0002-1280-1847</orcidid><orcidid>https://orcid.org/0000-0003-2731-6462</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0748-7983 |
| ispartof | European journal of surgical oncology, 2023-09, Vol.49 (9), p.106954-106954, Article 106954 |
| issn | 0748-7983 1532-2157 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2829430071 |
| source | Elsevier ScienceDirect Journals |
| subjects | Endometrial cancer Local recurrence Recurrence Survival TP53-Mutation |
| title | Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A13%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patterns%20of%20recurrence%20in%20surgically%20treated%20women%20for%20TP53-mutated%20endometrial%20carcinomas&rft.jtitle=European%20journal%20of%20surgical%20oncology&rft.au=Pain,%20Flore-Anne&rft.date=2023-09-01&rft.volume=49&rft.issue=9&rft.spage=106954&rft.epage=106954&rft.pages=106954-106954&rft.artnum=106954&rft.issn=0748-7983&rft.eissn=1532-2157&rft_id=info:doi/10.1016/j.ejso.2023.06.006&rft_dat=%3Cproquest_cross%3E2829430071%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2829430071&rft_id=info:pmid/37349159&rft_els_id=S0748798323005437&rfr_iscdi=true |